Researchers at Northwestern University have found a molecular pathway that prevents the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function. Adding a specific chemotherapy drug combination may protect young women's reproductive health during cancer treatment.
Researchers used parallel PET/MR imaging to map chemotherapy distribution before surgery, improving risk stratification and patient management. This study suggests simultaneous PET/MR imaging can benefit patients by predicting cancer recurrence and avoiding unnecessary chemotherapy.
The EORTC BOS 2 trial aims to improve outcomes for patients with resectable liver metastases from colorectal cancer by testing the efficacy of bevacizumab or panitumumab added to standard peri-operative FOLFOX 4 chemotherapy. The trial plans to accrue 360 patients in 50 sites across ten countries.
Researchers found that crizotinib boosts median disease progression time to 7.7 months, compared to 3 months with standard chemotherapy, in patients with non-small cell lung cancer harboring an abnormal ALK gene.
Doctors at WashU Medicine have shown that testing cervical tumors before treatment can predict whether patients will do well with standard chemotherapy. The study supports personalized medicine for cervical cancer, a tumor normally treated with a one-size-fits-all approach.
The EORTC trial 26951 found that CpG island methylator phenotype status and MGMT promoter methylation are key factors in determining which patients benefit from PCV chemotherapy. The study suggests that other molecularly defined subsets of grade III tumors may also respond to treatment.
A study from Western University has identified the Numb-p53 pathway as a key mechanism underlying chemotherapy resistance in triple-negative breast cancer. By targeting this pathway, researchers hope to develop novel therapies that can sensitize cancer cells to chemotherapy.
Cancer chemotherapy can cause peripheral neuropathy and delay recovery after bone marrow transplantation. Researchers at Albert Einstein College of Medicine discovered that nerve damage in the bone marrow also causes anemia by impairing hematopoietic stem cell regeneration.
Researchers found that intraventricular chemotherapy can palliate associated symptoms in patients with leptomeningeal carcinomatosis from non-small cell lung cancer. The study shows that 20 of 69 patients achieved normal ICP, and careful patient selection is recommended for successful treatment.
A new study identifies osteopontin as a potential new leukemia treatment target. The protein helps leukemia cells avoid the effects of chemotherapy by appearing dormant in the bone marrow environment.
Researchers identified an eight-gene signature that correlates with chemotherapy outcome in lung and breast cancer patients. The gene signature, which includes the receptor for growth factor EGF, helps predict relapse-free survival after chemotherapy.
A Mayo Clinic study found gene variations that can predict chemotherapy-induced peripheral neuropathy, a debilitating condition affecting 20-30% of cancer patients. The study implicates genes EPHA5, ARHGEF10, and PRX, enabling clinicians to individualize treatment and improve patient outcomes.
A Phase III clinical trial found that adding cetuximab to chemotherapy enables previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis. The combination also extends median overall survival by 10 months compared to chemotherapy alone.
New research reveals chemotherapy activates the body's immune system to target and destroy cancer cells. The treatment converts dying tumors into therapeutic vaccines, boosting the host's immune response against cancer.
A randomized phase 3 trial found that duloxetine reduced pain from chemotherapy-induced peripheral neuropathy compared to placebo. Patients who received platinums showed greater benefits from duloxetine.
A UK study found that epigenetic changes play a key role in the development of chemotherapy resistance in bladder cancer. The researchers identified DNA hypermethylation as a potential biomarker to predict response to treatment, which could increase pathological complete response rates and spare nonresponders from adverse events.
A prospective study found that children with low-risk retinoblastoma do not need postoperative chemotherapy to prevent disease recurrence or metastasis. The results suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment or even forego it altogether.
Bioengineering researchers at UC Santa Barbara found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at targeting and delivering anti-cancer drugs to breast cancer cells. The rod-shaped nanoparticles were engineered with an antibody called trastuzumab t...
A study published in the Journal of Clinical Investigation found that TGF-β is highly expressed in triple negative breast cancer cells after chemotherapy. In a mouse model, blocking TGF-β prevented tumor recurrence and enhanced chemotherapy action against triple negative breast cancer.
Researchers evaluated CT scans of patients with localized esophageal cancer before and after chemotherapy to identify changes in tumor texture. Smaller change in skewness following chemotherapy was a significant prognostic factor, with median overall survival increasing from 11.1 months to 36.1 months.
Researchers discover gene FBH1 crucial for chemotherapy's effectiveness in killing cancer cells. By understanding the role of FBH1, doctors can tailor treatment to individual patients based on genetic fingerprint.
Researchers at UCLA's Jonsson Comprehensive Center have identified liposarcoma tumors that can be imaged by PET scanning using a tracer substance known as FAC, and found these tumors are sensitive to chemotherapy. This discovery has translational potential for liposarcoma patients and may lead to more effective treatment strategies.
A clinical trial at Dana-Farber Cancer Institute found that intensified chemotherapy significantly reduces relapse odds for young patients with B-precursor acute lymphoblastic leukemia (B-ALL). The treatment regimen improved event-free survival rates to 76% five years after complete remission.
Scientists have identified an 'immune system kill switch' that triggers the destruction of blood stem cells in response to severe stress, such as chemotherapy or systemic infections. Blocking this internal signal could prevent death after chemotherapy and boost recovery from infection.
A new study conducted by Mayo Clinic reveals that sentinel lymph node surgery can accurately identify residual breast cancer in lymph nodes after chemotherapy, with a success rate of 91%. The procedure removed only a few lymph nodes, reducing surgical complications, and found complete eradication of cancer in 40% of patients.
A clinical trial testing this hypothesis should begin soon, combining chemotherapy agents with a new approach to target the immune system. The study found that blocking negative immune system activation increases the efficiency of chemotherapy.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
A new study demonstrates that a targeted therapy, selumetinib, and chemotherapy work better together than chemotherapy alone in treating patients with KRAS-mutant non-small cell lung cancer. The combination improved patient survival by 3.2 months and showed significant tumor shrinkage, offering hope for a potential new treatment strategy.
A study using PET/CT imaging found statistically significant decreases in regional brain metabolism associated with symptoms of chemo brain phenomenon. Researchers hope to establish a prospective study to improve treatment for patients experiencing this debilitating condition.
Researchers at the University of New South Wales have developed a non-toxic nanoparticle that can deliver nitric oxide to specific cancer cells, reducing chemotherapy doses by a factor of five. This could lead to improved treatment outcomes and reduced side effects for neuroblastoma patients.
A nationwide study led by Dana-Farber Cancer Institute found that 69% of advanced lung cancer and 81% of advanced colorectal cancer patients believe chemotherapy can cure their disease. However, skilled clinicians can set realistic expectations without losing hope or trust.
Guang Yue's 2-year NIH grant aims to investigate the impact of chemotherapy on white matter integrity and corresponding neurophysiological function. The study will explore structural changes in the corpus callosum and corticospinal tract, shedding light on the underlying causes of neurological side effects.
A Wake Forest Baptist researcher discovered that high levels of the MN1 gene accelerate Acute Myeloid Leukemia (AML) and reduce chemotherapy's effectiveness. The study found that the p53 protein is not functioning properly in cells expressing high levels of MN1, leading to a poorer prognosis.
Combining chemotherapy and immunotherapy results in enhanced anti-tumor effect, contrary to previous assumption that they would cancel each other out. The mechanism involves the upregulation of mannose-6-phosphate receptor on tumor cells, which is triggered by autophagy.
A phase III trial shows that crizotinib is more effective than standard chemotherapy in response rates and progression-free survival, with improved quality of life. The study compared 347 patients with previously treated ALK-positive lung cancer and found significant benefits for those on the crizotinib arm.
A new study by USC researchers shows that controlled fasting enhances the effectiveness of radiation therapy in treating gliomas, a type of brain tumor with a median survival of less than two years. Fasting improved survival rates in mice treated with radiation therapy alone or in combination with chemotherapy.
Researchers identify a subpopulation of cancer stem cells that display resistance to chemotherapy and contribute to tumor progression. The study suggests a new therapeutic strategy by targeting these cancer stem cells with a combination of standard chemotherapy and signaling pathway inhibitors.
A recent meta-analysis by researchers at Moffitt Cancer Center found that breast cancer patients who received chemotherapy had slight cognitive impairments in verbal and visuospatial abilities. The study suggests that these deficits can be managed through awareness and compensatory strategies, improving daily life for affected individu...
Infants born to mothers who received chemotherapy during pregnancy had lower birth weights but no higher risk of birth defects or blood disorders. The study suggests that breast cancer treatment during pregnancy is possible and prioritizing full-term delivery may be crucial for minimizing risks.
The study found that the absence or downregulation of the LRP1B gene is associated with chemoresistance in high-grade serous ovarian cancer. Additionally, tumors that initially responded to chemotherapy but later became resistant evolved further than those that were resistant from the outset.
Researchers have confirmed that normalizing blood vessels by blocking oxygen sensor PHD2 can make chemotherapy more effective. This strategy also reduces the harmful side effects of chemotherapy on healthy organs.
A recent study found that patients who received chemotherapy following removal of periampullary cancer experienced improved overall survival compared to those who did not receive chemotherapy. The study also suggested that gemcitabine therapy provided the most significant survival benefit, with a median survival time of 43.1 months.
Researchers found that perioperative chemotherapy improved overall survival in patients with limited large cell neuroendocrine tumors or small-cell lung cancer after surgery. The study of 74 patients showed a significant difference in overall survival between those who received chemotherapy and those who did not.
A Vanderbilt-led study identified a gene expression pattern linked to resistance to breast cancer chemotherapy. The researchers found that tumors with low concentrations of the dual specificity protein phosphatase 4 (DUSP4) were more resistant to chemotherapy, suggesting new therapy options for patients with specific subtypes of breast...
A clinical trial found that duloxetine reduced painful tingling feelings caused by chemotherapy in 59 percent of patients. The study suggests that this antidepressant may be an effective treatment for chemotherapy-induced peripheral neuropathy pain.
A study by Weizmann Institute scientists reveals that leukemia recurrence is often caused by 'cancer stem cells' that divide slowly, evading chemotherapy drugs. These cells can give rise to new rapidly-dividing cancer cells, making them a key target for new treatment approaches.
A new study shows that Breast MRI provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination. MRI size measurements were superior to clinical examination at all time points, predicting both complete tumor response and residual cancer burden.
A new study suggests that a protein called heat shock factor-1 (HSF-1) is involved in chemotherapy-related heart damage. Researchers propose targeting HSF-1 in the heart as a potential therapy to prevent cardiac damage, potentially leading to improved outcomes for cancer patients undergoing chemotherapy.
A recent study suggests a positive correlation between tumor size and chemotherapy efficacy in surgically resected patients with node-negative non-small cell lung cancer. The study found no clear threshold for tumor size that correlated with a benefit from chemotherapy.
Researchers developed gene expression signatures to predict breast cancer patient responses to chemotherapy. The signatures, based on TOP2A and β-tubulin, accurately predicted complete response rates and combined indices improved accuracy.
Researchers at Fred Hutchinson Cancer Center have successfully transplanted gene-modified blood stem cells into brain cancer patients to protect their bone marrow against chemotherapy's toxic effects. The study showed that two patients survived longer than predicted, with one remaining alive for over three years.
Researchers identified a group of patients with high immune response gene expression who are more likely to have their tumors completely eradicated by pre-operative chemotherapy. Patients with HER2-positive and ER-negative/HER2-negative subtypes showed better treatment outcomes.
Researchers at Moffitt Cancer Center found that breast cancer survivors who underwent chemotherapy and/or radiation therapy performed worse on cognitive tests than those who did not have cancer. The study's findings suggest long-term cognitive effects of these therapies need further investigation.
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Researchers from the University of Hull have identified a family of proteins associated with chemotherapy resistance in breast cancer patients. The 14-3-3 protein family was found to be twice as prevalent in resistant patients, suggesting its potential use as a predictive test for clinical decision-making.
A large international study found that chemotherapy is an effective alternative to bone marrow transplants for young leukemia patients who fail induction therapy. The study identified a subset of patients with high cure rates after additional chemotherapy, improving overall survival rates.
A harmless human virus, RT3D, has shown promise in boosting the effects of chemotherapy drugs in advanced head and neck cancer patients. In a Phase I/II trial, approximately one-third of patients experienced tumor shrinkage and disease stabilization.
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Researchers have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models. The results show that imipramine blue stops tumor invasion and enhances the efficacy of chemotherapy.